Poster

Application of PBPK Modelling to Explore Complex Food Effects on Trospium Chloride Pharmacokinetics

Discover how PBPK modeling with Simcyp mechanistically explains the formulation-dependent negative food effect of trospium…

CertaraJune 26, 2026

Poster

Cross-Version Simcyp Simulator Performance Assessment Using a Bioequivalence Framework for EMA Qualification

Learn how Certara used a bioequivalence-based TOST framework to demonstrate that Simcyp Simulator versions V20–V24…

CertaraJune 26, 2026

Poster

PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity

Explore how PBPK modelling evaluates the in vivo tumour-targeting specificity of bispecific monoclonal antibodies (bsmAbs),…

CertaraJune 25, 2026

Poster

Sex-Specific Bioequivalence Outcomes: PBPK Insights into Gastric Emptying Variability

Discover how sex-dependent within-subject variability in gastric emptying time influences supersaturation, precipitation, and Cmax in…

CertaraJune 25, 2026

Poster

PBPK Modelling of Formulation-Dependent Food Effects for Itraconazole Oral Solution

Explore mechanistic PBPK modelling of itraconazole oral solution, revealing how bile salt–cyclodextrin interactions drive a…

CertaraJune 25, 2026

Guide

How to Build a Best Practice Global Value Dossier With a Decision-first Strategy

Learn how a decision-first approach to value dossier preparation helps teams build pharma value dossiers…

CertaraJune 25, 2026

Poster

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Leiden University and EFSA researchers present the PBMC TXG-MAPr — a network-based transcriptomic tool mapping…

CertaraJune 23, 2026

Poster

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Research from Leiden University and EFSA characterizing interindividual toxicodynamic variability using peripheral blood mononuclear cells…

CertaraJune 23, 2026

Announcement

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…

Danielle PillsburyJune 23, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Application of PBPK Modelling to Explore Complex Food Effects on Trospium Chloride Pharmacokinetics

Cross-Version Simcyp Simulator Performance Assessment Using a Bioequivalence Framework for EMA Qualification

PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity

Sex-Specific Bioequivalence Outcomes: PBPK Insights into Gastric Emptying Variability

PBPK Modelling of Formulation-Dependent Food Effects for Itraconazole Oral Solution

How to Build a Best Practice Global Value Dossier With a Decision-first Strategy

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Newsletter sign up

Quick links

Solutions

Contact